EA032475B1 - Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение - Google Patents

Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение Download PDF

Info

Publication number
EA032475B1
EA032475B1 EA201400345A EA201400345A EA032475B1 EA 032475 B1 EA032475 B1 EA 032475B1 EA 201400345 A EA201400345 A EA 201400345A EA 201400345 A EA201400345 A EA 201400345A EA 032475 B1 EA032475 B1 EA 032475B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
sequence represented
sequence
heavy chain
light chain
Prior art date
Application number
EA201400345A
Other languages
English (en)
Russian (ru)
Other versions
EA201400345A1 (ru
Inventor
Дейвид Пол Хамфрис
Даниел Джон Лайтвуд
Керри Луисе Тайсон
Дейвид Эдуард Ормонде Найт
Карине Жаннине Мадлен Эрве
Джоанне Элизабет Комрсон
Маттью Джон Тимоти Пейдж
Эндрью Чарльз Пейн
Никола Луисе Фишер
Брендон Маккензи
Маттью Кокс
Original Assignee
Юсб Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032475(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсб Фарма С.А. filed Critical Юсб Фарма С.А.
Publication of EA201400345A1 publication Critical patent/EA201400345A1/ru
Publication of EA032475B1 publication Critical patent/EA032475B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201400345A 2011-09-16 2012-09-10 Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение EA032475B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US201261638731P 2012-04-26 2012-04-26
PCT/GB2012/052222 WO2013038156A1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

Publications (2)

Publication Number Publication Date
EA201400345A1 EA201400345A1 (ru) 2014-09-30
EA032475B1 true EA032475B1 (ru) 2019-06-28

Family

ID=46881094

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400345A EA032475B1 (ru) 2011-09-16 2012-09-10 Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение

Country Status (30)

Country Link
US (2) US10752676B2 (enExample)
EP (2) EP3617227A3 (enExample)
JP (3) JP6152107B2 (enExample)
KR (1) KR20140063825A (enExample)
CN (2) CN108424449A (enExample)
AU (1) AU2012307157B2 (enExample)
BR (1) BR112014006175B1 (enExample)
CA (1) CA2848611A1 (enExample)
CL (1) CL2014000491A1 (enExample)
CO (1) CO6930310A2 (enExample)
CY (1) CY1121673T1 (enExample)
DK (1) DK2758432T3 (enExample)
EA (1) EA032475B1 (enExample)
EC (1) ECSP14013316A (enExample)
ES (1) ES2729278T3 (enExample)
HK (1) HK1199463A1 (enExample)
HR (1) HRP20190917T1 (enExample)
HU (1) HUE043661T2 (enExample)
IL (1) IL231167A0 (enExample)
LT (1) LT2758432T (enExample)
MX (1) MX2014002769A (enExample)
PE (1) PE20141547A1 (enExample)
PH (1) PH12014500456A1 (enExample)
PL (1) PL2758432T3 (enExample)
PT (1) PT2758432T (enExample)
SG (2) SG10201701055WA (enExample)
SI (1) SI2758432T1 (enExample)
TN (1) TN2014000101A1 (enExample)
WO (1) WO2013038156A1 (enExample)
ZA (1) ZA201402760B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
WO2014176276A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
WO2015123767A1 (en) * 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
HK1246196A1 (zh) * 2015-04-15 2018-09-07 Medimmune, Llc 用於治疗艰难梭菌(clostridium difficile)感染和相关疾病的方法
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
RU2761249C2 (ru) * 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999010008A1 (en) 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0517592B1 (pt) 2004-12-27 2016-03-15 Huntsman Corp Australia Pty Ltd formulação agroquímica sólida, método para preparar a mesma, e, formulação de concentração de suspensão
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP5592792B2 (ja) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
JP2011512817A (ja) * 2008-02-28 2011-04-28 スリーエム イノベイティブ プロパティズ カンパニー クロストリジウム・ディフィシル胞子に対する抗体及びその使用
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
US8709428B2 (en) * 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
MX339253B (es) * 2010-04-15 2016-05-18 Progenics Pharm Inc Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
US9771416B2 (en) * 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2921502A4 (en) * 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9815886B2 (en) * 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABCOCK GREGORY J; BROERING TERESA J; HERNANDEZ HECTOR J; MANDELL ROBERT B; DONAHUE KATHERINE; BOATRIGHT NAOMI; STACK ANNE M; LOWY: "Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 11, 1 November 2006 (2006-11-01), US, pages 6339 - 6347, XP009109025, ISSN: 0019-9567, DOI: 10.1128/IAI.00982-06 *
GREG HUSSACK AND JAMSHID TANHA: "Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives", TOXINS, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI) AG., CH, vol. 2, no. 5, 1 May 2010 (2010-05-01), CH, pages 998 - 1018, XP002686777, ISSN: 2072-6651, DOI: 10.3390/toxins2050998 *

Also Published As

Publication number Publication date
AU2012307157A1 (en) 2014-04-24
AU2012307157B2 (en) 2017-08-03
JP2015501286A (ja) 2015-01-15
EP3617227A2 (en) 2020-03-04
BR112014006175B1 (pt) 2020-02-11
ECSP14013316A (es) 2014-08-29
JP6603685B2 (ja) 2019-11-06
EP2758432B1 (en) 2019-03-06
CN103958544B (zh) 2018-04-24
ZA201402760B (en) 2016-03-30
SG10201701055WA (en) 2017-03-30
MX2014002769A (es) 2014-06-11
HK1199463A1 (en) 2015-07-03
BR112014006175A2 (pt) 2017-04-04
EP3617227A3 (en) 2020-06-03
US20140348844A1 (en) 2014-11-27
EP2758432A1 (en) 2014-07-30
US10752676B2 (en) 2020-08-25
US20200377578A1 (en) 2020-12-03
HUE043661T2 (hu) 2019-08-28
TN2014000101A1 (en) 2015-07-01
IL231167A0 (en) 2014-04-30
KR20140063825A (ko) 2014-05-27
PL2758432T3 (pl) 2019-08-30
EA201400345A1 (ru) 2014-09-30
PE20141547A1 (es) 2014-10-25
CN103958544A (zh) 2014-07-30
ES2729278T3 (es) 2019-10-31
PT2758432T (pt) 2019-06-14
JP6152107B2 (ja) 2017-06-21
CN108424449A (zh) 2018-08-21
JP2017149773A (ja) 2017-08-31
WO2013038156A1 (en) 2013-03-21
HRP20190917T1 (hr) 2019-07-26
DK2758432T3 (da) 2019-06-03
CL2014000491A1 (es) 2014-12-26
SG11201400193SA (en) 2014-05-29
CA2848611A1 (en) 2013-03-21
NZ623293A (en) 2016-05-27
CY1121673T1 (el) 2020-07-31
PH12014500456A1 (en) 2014-04-14
CO6930310A2 (es) 2014-04-28
JP2020037555A (ja) 2020-03-12
SI2758432T1 (sl) 2019-07-31
LT2758432T (lt) 2019-06-10

Similar Documents

Publication Publication Date Title
EA032475B1 (ru) Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение
JP7405616B2 (ja) 生体直交型組成物
EP3197501B1 (en) Biological materials and uses thereof
JP2021532114A (ja) 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
UA128383C2 (uk) Антитіло до тау-білка та спосіб його застосування
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
CN106103483A (zh) 抗hpv和hpv相关的疾病的新疫苗
KR20120115495A (ko) 위장 장애의 치료
JP2015535224A (ja) 抗カンピロバクター・ジェジュニ（ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ）抗体及びその使用
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
KR20220134569A (ko) 8-클로로-n-(4-(트리플루오로메톡시)페닐)퀴놀린-2-아민의 비정질 고체 분산체
EP3694490B1 (en) Vaccine composition against streptococcus pneumoniae, use thereof for immunizing an individual against s. pneumoniae and method of preparation
US20160130328A1 (en) Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications
US20250213717A1 (en) Hydrogel formulations for vlp therapeutics
WO2025006989A2 (en) Methods for detection and treatment of cancer
HK1230629A1 (en) Novel vaccines against hpv and hpv-related diseases
BR122025020631A2 (pt) Anticorpos antagonistas isolados que se ligam especificamente a pd-1 ou porção de ligação ao antígeno dos mesmos, seus métodos de produção, seus usos, composições farmacêuticas, polinucleotídeos, vetores, células hospedeiras, anticorpo anti-idiotípico e kit
NZ623293B2 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
HK1241701A1 (en) Biological materials and uses thereof
CA2890580A1 (en) Clostridium difficile vaccine

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU